Journal: Frontiers in oncology

Article Title: Ipriflavone Suppresses Growth of Esophageal Squamous Cell Carcinoma Through Inhibiting mTOR In Vitro and In Vivo .

doi: 10.3389/fonc.2021.648809

Figure Lengend Snippet: FIGURE 4 | Ipriflavone is a novel mTOR inhibitor. (A) Effect of Ipriflavone on EGF‐induced kinase signaling molecules in JB6 cells. After serum starvation for 24 h, cells were treated with different doses of Ipriflavone for 6 h followed by EGF treatment for 30 min. various signaling molecules were analyzed by Western blotting. (B) Effect of Ipriflavone on various signaling molecules in KYSE450 ESCC cells. Cells were treated with Ipriflavone for 24 h and signaling molecule proteins were examined by Western blotting. (C) Effect of Ipriflavone on mTOR kinase activity was assessed by an in vitro kinase assay using active mTOR and inactive p70S6K proteins. The activity of mTOR was determined by Western blotting using a phosphorylated p70S6K antibody. AZD8055 (mTOR inhibitor) was used as a positive control. For all data, similar results were observed from three independent experiments and band density was measured using the Image J (NIH) software program. The asterisk (*) indicates a significant (p < 0.05) difference. (D) Modeling of Ipriflavone binding with mTOR. ATPgS (D, upper left panel) and Ipriflavone (D, upper right panel) binding with mTOR at the ATP binding pocket. (D, lower panel) Ligand Interaction Diagram (LID) of the binding. The Ipriflavone is shown as stick. LID legend is shown below.

Article Snippet: The inactive p70S6K recombinant protein (100 ng, Signalchem) and ATP (Cell Signaling Technology) were added and the mixtures were incubated at 30°C for 30 min.

Techniques: Western Blot, Activity Assay, In Vitro, Kinase Assay, Positive Control, Software, Binding Assay

Journal: Trends in Pharmacological Sciences

Article Title: Malnutrition vaccines for an imminent global food catastrophe

doi: 10.1016/j.tips.2022.08.007

Figure Lengend Snippet: Selected malnutrition vaccines in development

Article Snippet: Malaria , Mosquirix R21/Matrix-M PfSPZ Sporozoite , GSK-PATH SII–Oxford University–Sanaria , EMA Licensure and WHO approval infants 6–17 months Phase 2–3 Phase 2–3 , [ , ] .

Techniques: Vaccines, Infection

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Growth Differentiation Factor‐15 Deficiency Inhibits Atherosclerosis Progression by Regulating Interleukin‐6–Dependent Inflammatory Response to Vascular Injury

doi: 10.1161/JAHA.112.002550

Figure Lengend Snippet: Oligonucleotides Used for Genotyping Polymerase Chain Reaction

Article Snippet: R21 reverse , 5′‐GGC CAC CAG GTC ATC ATA AG‐3′ , , Metabion, Planegg‐Martinsried, Germany.

Techniques: Sequencing, Amplification, Knock-Out